For patients with mCRPC with bone metastases, the addition of radium-223 to enzalutamide therapy is associated with improved overall survival.

Scientists need a better understanding of the chemistry of radium to be able to target the isotope radium-223 (Ra-223) to cancer cells. Once delivered, Ra-223 can destroy those cells with alpha ...

Bayer’s XOFIGO® plus enzalutamide demonstrates significant OS benefit in PEACE-3 trial in patients with mCRPC with bone metastases ...

A phase 2 trial showed that olaparib plus radium 223 prolonged progression-free survival in a subset of patients with castration-resistant prostate cancer and bone metastases. Radiographic progression ...

Cedars-Sinai’s center provides personalized, multidisciplinary care for RA and related conditions, improving patient outcomes and quality of life. Dr. Jon Giles' research explores autoimmune disease ...

This is an excellent question because conclusions from evidence-based medicine studies of this issue are sparse in comparison with guidelines from expert panels. The question itself may be turned on ...